Skip to main content

Phosphodiesterase Type 5 (PDE-5) Inhibitor Use Among Pregnant Women and Women of Reproductive Age in the United States

Basic Details
Date
Type
Presentation
Medical Product
phosphodiesterase type 5 (PDE5) inhibitor
Materials

Phosphodiesterase Type 5 (PDE-5) Inhibitor Use Among Pregnant Women and Women of Reproductive Age in the United States

Information
Time Period
January 1, 2001 to March 31, 2018
Population / Cohort
Females 15-50 years of age
Host

35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Related Assessment(s)
Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019
Sentinel Drug Study: Phosphodiesterase Type 5 (PDE5) Inhibitors & Exposure in Pregnancy
Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women
Presenter(s)

Wei Liu, Talia Menzin, Corinne M. Woods, Nicole Haug, Jie Li, Justin A. Mathew, Christine P. Nguyen, Grace P. Chai, David Moeny, Mayura Shinde